Since its incorporation in 2001, Keosys has been focused on advancing the medical imaging field. Following several years of experience in the clinical practice space selling workstations and storage solutions to radiologists across the world, Keosys ventured into the clinical research field in 2008. Since then Keosys has established itself as a leading international imaging CRO, working in all major continents on over 180 trials, leading to drug approvals in all major territories. Today Keosys offers advanced scientific and operational services to major pharmaceutical companies, helping them with their growing imaging needs during their drug development process.

our-history-icon

OUR HISTORY

KEOSYS MEDICAL IMAGING

Tramadol Buy Online Cheap Incorporation of Keosys Medical Imaging in Saint-Herblain, France with advanced knowledge in both medical imaging and telecommunication.

2001

2003

POSITOSCOPE

Tramadol Sale Online Uk Launch of our patented Positoscope, the first electronic light box for PET/CT centralized interpretation with advanced file sharing functionalities.

PACS SYSTEM

Tramadol Cheapest

Launch of our vendor-neutral PACS system and CD burner, including fused hybrid imaging viewing capabilities.

2005

2006

ADVANCED NUCLEAR MEDICINE WORKSTATIONS

https://www.goedkoopvliegen.nl/uncategorized/sruckbxn9 Extension of our product offering with the development of Advanced Nuclear Medicine Workstations (25% share of the French market within a few years).

IMAGING PROVIDER FOR H10

https://www.lcclub.co.uk/3kgeu415gb

Keosys acts as imaging provider for H10, the first multicenter European study involving image-based treatment arm selection, in partnership with EORTC.

2007

2008

IMAGING CRO

Order Tramadol India

Keosys focuses on becoming an imaging CRO and providing imaging services in clinical trials.

IMAGYS PLATFORM

https://asperformance.com/uncategorized/tzcyxlzk

https://www.worldhumorawards.org/uncategorized/yg9gtzku8y Keosys works with academics, medical experts and pharmaceutical companies to design and implement a state-of-the-art, web-based imaging platform to be used in clinical trials. The IMAGYS platform is born.

2009

2010

FIRST PHASE III STUDY

https://www.jamesramsden.com/2024/03/07/y8bcrbi41q

https://elisabethbell.com/xmexdoy9yu Signature of our first Phase III study with a U.S.-based major pharmaceutical company (in lymphoma).

REMOTE READING SOLUTIONS

https://www.mominleggings.com/j4rhwa0chk

Launch of our proprietary Remote Reading Solutions (patented), allowing physicians to view and analyze multi-modality medical images with diagnostic grade quality.

2011

2013

KEOSYS U.S. AND ASIA

https://giannifava.org/ihl7cal0f

Launch of our U.S. and Asia offices. Keosys joins a large international trial in the Asian market.

INVESTMENT FROM JMC FAMILY OFFICE

JMC Family Office, based in NYC, invests in Keosys to help further the growth of the company and expand its capabilities across the world. Launch of a big data research project with the aim of improving operational efficiencies and lowering costs of clinical trials.

2015

2016

FDA AND EMA CLEARANCE

Keosys completes a large international Phase III project leading FDA and EMA clearance (No 483 letters from FDA).

EARLY-STAGE STUDIES

Keosys begins working on early-stage diagnostic studies involving complex read designs and early-stage development.

2017

2018

Dosimetry services

Keosys launches its centralized dosimetry services including site calibration activities.

Operational Dashboards

Keosys releases a major overhaul of its IMAGYS platform including operational and scientific dashboards giving users access to real time imaging data.

2019

2020

Major big pharma contract

Keosys continues its growth by signing a multi-year multi study contract with a top 5 pharmaceutical company.

Today

The company continues to grow and evolve its imaging platform, read system and its value-added features to best meet the needs of researchers across the globe.

2021